Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors.
about
Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemiaOncogenic kinase fusions: an evolving arena with innovative clinical opportunitiesCurrent concepts in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemiaPhase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation.Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance.Growth of tyrosine kinase inhibitor-resistant Philadelphia-positive acute lymphoblastic leukemia: Role of bone marrow stromal cellsFirst report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia.Susceptibility of Ph-positive all to TKI therapy associated with Bcr-Abl rearrangement patterns: a retrospective analysis.Imatinib resistant BCR-ABL1 mutations at relapse in children with Ph+ ALL: a Children's Oncology Group (COG) study.The role of dasatinib in the management of chronic myeloid leukemiaPatients with Philadelphia-positive leukemia with BCR-ABL kinase mutations before allogeneic transplantation predominantly relapse with the same mutation.Targeting paediatric acute lymphoblastic leukaemia: novel therapies currently in developmentRapid clonal shifts in response to kinase inhibitor therapy in chronic myelogenous leukemia are identified by quantitation mutation assays.Allografting for Bosutinib, Imatinib, Nilotinib, Dasatinib, and Interferon Resistant Chronic Myeloid Leukemia without ABL Kinase Mutation.Environment-mediated drug resistance in Bcr/Abl-positive acute lymphoblastic leukemiaCombination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study.BCR-ABL fusion transcript types and levels and their interaction with secondary genetic changes in determining the phenotype of Philadelphia chromosome-positive leukemias.Laboratory practice guidelines for detecting and reporting BCR-ABL drug resistance mutations in chronic myelogenous leukemia and acute lymphoblastic leukemia: a report of the Association for Molecular Pathology.Philadelphia chromosome-positive acute lymphoblastic leukemia.Philadelphia chromosome-positive acute lymphoblastic leukemia in children: new and emerging treatment options.New developments in the treatment of chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia.Philadelphia chromosome-positive acute lymphoblastic leukemia: current treatment and future perspectives.Managing Philadelphia chromosome-positive acute lymphoblastic leukemia: role of tyrosine kinase inhibitors.Role of tyrosine kinase inhibitors in the management of Philadelphia chromosome-positive acute lymphoblastic leukemia.Optimal pharmacotherapeutic management of acute lymphoblastic leukaemia in the elderly.BCR-ABL1 kinase domain mutations: methodology and clinical evaluation.Optimal approach to treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: how to best use all the available tools.Current and future management of Ph/BCR-ABL positive ALL.The role of ponatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia.An activating mutation of GNB1 is associated with resistance to tyrosine kinase inhibitors in ETV6-ABL1-positive leukemia.Givinostat, a type II histone deacetylase inhibitor, induces potent caspase-dependent apoptosis in human lymphoblastic leukemia.Treatment of Philadelphia Chromosome-Positive Acute Lymphocytic Leukemia.Molecular diagnostics, targeted therapy, and the indication for allogeneic stem cell transplantation in acute lymphoblastic leukemia.Acute lymphoblastic leukemia: a comprehensive review and 2017 updateClinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665.Activity of the Aurora kinase inhibitor VX-680 against Bcr/Abl-positive acute lymphoblastic leukemias.VE-cadherin Regulates Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Sensitivity to Apoptosis.Chronic myeloid leukemia 2011: successes, challenges, and strategies--proceedings of the 5th annual BCR-ABL1 positive and BCR-ABL1 negative myeloproliferative neoplasms workshop.Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia.Fall of the mutants: T cells targeting BCR-ABL.
P2860
Q24622397-59B1F93A-66D4-4D7E-BBD2-69A659853CCCQ26768158-C558DE80-17CA-47A6-B1A3-B583536841DEQ27025242-220C43E2-670D-4C50-87DB-81EB83259496Q33402841-F2F0F25B-C28C-47E8-935E-307F3BAEAB00Q33561227-586E968B-0705-4156-BDC5-09264A230BD1Q33597756-6E525ACB-7F6B-4194-A190-9ACB42C2E607Q33843477-002AB92A-569D-4A0F-AC50-7934C854E1EBQ34557165-CEEDB5A5-E17D-42C7-85DE-8433E63CD918Q34915917-75A6EEB4-311F-41E9-9C54-C07305A7EBB0Q35087994-FED36C6B-6B97-4E20-B1AA-121A74C3AEADQ35731623-3C22E4F6-E96D-49C6-8988-C6092CA3BDF1Q35967452-966AEFF1-897F-477A-B4F3-E11DA1DB29D5Q35998184-A52C5ABD-6D27-429D-8B22-D66503938CFFQ36169317-8A5E1A96-9F9E-4261-BF6A-B8E6D18C0386Q36194829-22F28B8B-7C6B-4671-99D0-9AA2F36B6ACFQ36751420-DE582824-148F-40CF-85FD-0542192F9A3DQ37003563-DD70E4BC-33CA-46AE-B43C-824A3AB4AC16Q37024667-F86AEF5C-4AF3-4BB7-B630-A73AE40C691DQ37613888-0B2CED69-BD87-48B9-9455-723C5FC42F0CQ37810967-59DE98F0-81E2-4B30-9935-0965F0C95498Q37836938-1614E0D8-89B0-4CB8-B89B-2A565E2E9838Q37862648-54E3B3B5-D5E0-49AE-B494-B715D2C6EE90Q37875969-BAC45F34-25F6-4CF7-91CE-387652A17147Q37887580-9A754228-6900-4B2A-8935-BEC05049159AQ37931235-5141F6F1-EB0F-4249-87CB-A3E998382390Q37974490-F58824E1-FA5A-47EA-B26B-7EDBF8D95044Q38023947-F120D131-D0D4-4F64-80AB-3BF62A21F8ECQ38194585-7B3C2317-73A3-45F9-A19A-55983713291EQ38375425-33A5A69A-9E11-4AE5-83C3-7071C85699E1Q38699035-F0D8BB1B-3997-45B9-98DF-4E4C28409DC9Q38723094-A1152574-3057-4DF4-9E05-33F69F761133Q38734309-B19F7567-3368-4290-B48D-D3A5BEDC023AQ39112294-81C72076-8212-4BEC-A12A-FCE6D41C7A6DQ39406969-0CEAA50C-9A59-4AD4-8B2B-6F3BB2371631Q39985910-A041F9F8-2295-4D85-818D-EDE1CEB1FEE3Q40491709-E1F1DDAF-7549-442E-AE16-F869E12E3ECCQ41581040-DF85B496-BC9A-4EB3-918C-16CADEBBC413Q41594071-6A637C29-AF26-4B8C-8F0A-1DF5D7282F7FQ41843107-9904781D-F98F-4CC3-8982-BC542DFD2CFDQ42324198-DFB64DC6-F1E8-4C01-977B-54BDEA7B9B14
P2860
Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors.
description
2008 nî lūn-bûn
@nan
2008 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Kinase domain point mutations ...... ith BCR-ABL kinase inhibitors.
@ast
Kinase domain point mutations ...... ith BCR-ABL kinase inhibitors.
@en
Kinase domain point mutations ...... ith BCR-ABL kinase inhibitors.
@nl
type
label
Kinase domain point mutations ...... ith BCR-ABL kinase inhibitors.
@ast
Kinase domain point mutations ...... ith BCR-ABL kinase inhibitors.
@en
Kinase domain point mutations ...... ith BCR-ABL kinase inhibitors.
@nl
prefLabel
Kinase domain point mutations ...... ith BCR-ABL kinase inhibitors.
@ast
Kinase domain point mutations ...... ith BCR-ABL kinase inhibitors.
@en
Kinase domain point mutations ...... ith BCR-ABL kinase inhibitors.
@nl
P2093
P2860
P50
P356
P1433
P1476
Kinase domain point mutations ...... ith BCR-ABL kinase inhibitors.
@en
P2093
C Cameron Yin
Deborah Thomas
Francis J Giles
Megan Breeden
Weiqiang Zhao
P2860
P304
P356
10.1002/CNCR.23666
P407
P577
2008-09-01T00:00:00Z